Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; 3Clinic...
Saved in:
Main Authors: | Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/2c960f49b0f844b0a10151a59a239b6a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
by: Wu R, et al.
Published: (2020) -
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
by: Haowei (Linda) Sun, et al.
Published: (2021) -
Recent Advances in the Treatment of Hemophilia: A Review
by: Marchesini E, et al.
Published: (2021) -
Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
by: Mairead O’Donovan, et al.
Published: (2021) -
Sports and Children with Hemophilia: Current Trends
by: Lorenzo Moretti, et al.
Published: (2021)